On Jun. 24, 2012, the U.S. Food and Drug Administration (FDA) announced it had approved HibMenCY (Menhibrix, GlaxoSmithKline), a new combination (meningococcal and Hib) vaccine for infants.

In October, the Advisory Committee on Immunisation Practice in the U.S. recommended HibMenCY-TT vaccination for infants at increased risk of meningococcal disease.

HibMenCY-TT may be given concomitantly with other routine infant vaccines. It induced antibodies against Hib as well as bactericidal activity against meningococcal serogroup C and Y without increasing the number of injections required.